An observational study in Patellar Instability and Trochlear Articular Cartilage Lesions, sponsored by Stefano Zaffagnini. Not yet recruiting at 1 site in Italy. Open to participants aged 14 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Stefano Zaffagnini · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a multicentre, international, non-profit observational study aimed at prospectively validating a personalized diagnostic and therapeutic algorithm based on the Dejour v3.0 classification in patients with recurrent objective patellar instability and trochlear dysplasia.
The primary objective is to compare treatment failure rates at 24 months between patients with severe trochlear dysplasia (trochlear bump >5 mm) treated with trochleoplasty and MPFL reconstruction, and a retrospective control group with similar trochlear morphology treated without trochleoplasty.
Secondary outcomes include clinical and functional outcomes assessed using validated scores (IKDC, Kujala, Tegner and BPII 2.0), cartilage status assessed by MRI using the MOAKS score, and postoperative complications, particularly arthrofibrosis.
Patients aged 14-49 years will be enrolled at IRCCS Istituto Ortopedico Rizzoli and Lyon Ortho Clinic. The study includes both a prospective cohort managed according to the Dejour v3.0 algorithm and a retrospective historical control cohort. Follow-up assessments will be performed up to 24 months after surgery.
The study is planned to start on October 1, 2026, with an expected completion date of September 30, 2029. A total sample size of 152 patients (76 per group) is planned.
Stefano Zaffagnini is the lead sponsor of 16 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study will be conducted within the facilities of the Orthopedic and Traumatology Clinic II Unit at the IRCCS Istituto Ortopedico Rizzoli and at the Lyon Ortho Clinic. Surgical procedures will be performed at both these institutions.
Patients will be asked to sign an informed consent during the hospital stay and after signing the informed consent will be asked to complete a questionnaire on the preoperative condition.
Clinical follow-up visits will be carried out at the outpatient clinics of the IRCCS Istituto Ortopedico Rizzoli as well as at the Lyon Ortho Clinic.
Inclusion Criteria study group:
Exclusion Criteria study group:
Inclusion Criteria control group:
Exclusion Criteria control group:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who performed preoperative imaging studies (MRI) that confirmed the diagnosis and the need for treatment based on the above mentioned criteria (type 3 dysplasia with a bump \>5mm). They are treated according to the Dejour v3.0 algorithm, which involves trochleoplasty combined with medial patellofemoral ligament (MPFL) reconstruction.
The control group includes patients with comparable anatomical characteristics who were previously treated without trochleoplasty.
Failure rates
Defined as reoperation for subsequent atraumatic patellar luxation or persistent instability at 24 months. They will be registered in the CRF during the follow-up visits or during the telephonic contact in case of missing follow-ups. This could also be assessed through the clinical documentation of the patient, in case of missing data.
Time frame: At 24 months
Start is estimated for Jun 2027; primary completion for Sep 2029, 27 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stefano Zaffagnini